Quest Partners LLC Increases Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Quest Partners LLC boosted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 264.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,398 shares of the company’s stock after acquiring an additional 1,014 shares during the period. Quest Partners LLC’s holdings in Krystal Biotech were worth $254,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co grew its position in shares of Krystal Biotech by 80.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 3,128 shares of the company’s stock valued at $557,000 after acquiring an additional 1,397 shares during the period. Lazard Asset Management LLC boosted its position in Krystal Biotech by 27.5% during the first quarter. Lazard Asset Management LLC now owns 1,308 shares of the company’s stock worth $232,000 after purchasing an additional 282 shares in the last quarter. Caxton Associates LP acquired a new stake in Krystal Biotech in the first quarter valued at approximately $232,000. Virtu Financial LLC purchased a new stake in shares of Krystal Biotech in the first quarter valued at approximately $640,000. Finally, GAMMA Investing LLC increased its position in shares of Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after buying an additional 93 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 14.10% of the stock is owned by company insiders.

Analyst Ratings Changes

KRYS has been the topic of a number of research analyst reports. Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday, November 5th. Chardan Capital upped their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech has an average rating of “Buy” and a consensus target price of $202.29.

Krystal Biotech Price Performance

KRYS stock opened at $196.52 on Wednesday. Krystal Biotech, Inc. has a 1 year low of $99.00 and a 1 year high of $219.34. The firm has a market capitalization of $5.65 billion, a PE ratio of 111.03 and a beta of 0.82. The business has a 50 day simple moving average of $179.69 and a 200-day simple moving average of $183.09.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. During the same period in the prior year, the business earned ($0.67) EPS. The firm’s quarterly revenue was up 879.9% on a year-over-year basis. On average, equities research analysts expect that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).